Researchers at the University of Auckland has entered one for the Cen - 209 clinical development, which is more than 10 years of research and development agreement for the university said Tuesday's statement.
Cen - 209 is intended to strengthen the solid tumor radiotherapy and hypoxia, which is anti-tumor effects of standard chemotherapy, the statement said. For example, in lung cancer patients, about half of tumor hypoxia region.
New drugs to destroy cancer cells hypoxia DNA work, and the normal, healthy tissue alone.
Cen - 209 Design and the University of Auckland Cancer Society Research Centre (ACSRC) researchers to create, use drugs within the tumor transport computer model to accurately predict drug's antitumor activity.
"Drug trafficking within our computer model developed to allow synthetic chemists to test their design theory, greatly reducing the discovery process, said:" Professor Michael Hay, who led ACSRC research chemist.
"Cen - 209 agents significantly improved in the past, it can penetrate the tumor class terms, this is it in the lab, combined with radiotherapy improved long-term or short course events reflect that," researcher Professor Bill Wilson.
According to the University of Auckland UniServices Ltd and between the California-based snow cover treatment, the company is a subsidiary of Varian Medical Systems, the agreement will have the exclusive right to the snow Cen - 209, it will develop, and with the British Journal of Cancer research trials.
Of Cen - 209 work is funded from the National Cancer Institute initiated a program of the climax, and the recent discovery from the Wilkins Center for Bio. Ongoing Cen - 209 preclinical studies and back-up compounds from the Auckland Medical Research Foundation, the trust originated in New Zealand Health Research Council of the tumor, funded the statement said.
0 评论:
发表评论